Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned ModelCompany AnnouncementGenmab to acquire Merus for USD 97.00 per share in an all-cash transaction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback